What is MapLight Therapeutics, Inc. 's cash & equivalents?

MapLight Therapeutics, Inc. (MPLT) reported cash & equivalents of $55.71M in Q1 2026.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

MapLight Therapeutics, Inc. MPLT Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers SquibbBMY

$9.57B-12.0%

Johnson & JohnsonJNJ

$21.69B-43.6%

Neurocrine BiosciencesNBIX

$274.5M+35.8%

Acadia PharmaceuticalsACAD

$282.21M+29.6%

AbbVieABBV

$9.39B+81.5%

LBR

LB Pharmaceuticals Inc Common StockLBRX

$320.68M—

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

See full

Market cap$1.39B—

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's cash & equivalents?: MapLight Therapeutics, Inc. (MPLT) reported cash & equivalents of $55.71M in Q1 2026.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.